NCT00030875View on ClinicalTrials.gov

Bortezomib in Treating Patients With Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 19, 2002

Primary Completion Date

July 21, 2005

Study Completion Date

December 21, 2009

Conditions
Lymphoma
Interventions
DRUG

bortezomib

Trial Locations (10)

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

British Columbia Cancer Agency, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

L8V 5C2

Margaret and Charles Juravinski Cancer Centre, Hamilton

K7L 5P9

Kingston Regional Cancer Centre, Kingston

N6A 4L6

Cancer Care Ontario-London Regional Cancer Centre, London

M4N 3M5

Toronto Sunnybrook Regional Cancer Centre, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

H1T 2M4

Maisonneuve-Rosemont Hospital, Montreal

H2W 1S6

McGill University, Montreal

Sponsors
All Listed Sponsors
lead

NCIC Clinical Trials Group

NETWORK

NCT00030875 - Bortezomib in Treating Patients With Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter